Enteric Disease Testing Industry Overview

The global enteric disease testing market size was valued at USD 3.81 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 2.7% from 2023 to 2030. Vital drivers of this market include technological advancements and supportive government funding in emerging economies. Furthermore, growing global demand for early diagnostics is expected to enhance the applicability of the market, fueling its growth.

Gather more insights about the market drivers, restrains and growth of the Enteric Disease Testing Market

In regions such as Asia, Africa, and Latin America, the prevalence of enteric infections, including salmonella, campylobacter, escherichia coli, and norovirus, remains significantly high. According to the National Library of Medicine, as of 2018, a case fatality rate of 1% is observed in enteric fever cases in the Asia and Africa regions. Consequently, there is an increasing demand for enteric disease testing to enable accurate and timely diagnoses. Moreover, there is increasing awareness among individuals, healthcare providers, and government entities regarding the importance of early detection and effective management of enteric diseases. As a result, various organizations and government bodies are undertaking initiatives to enhance awareness, implement screening programs, and advocate for the utilization of diagnostic tests, thereby stimulating market growth.

The traditional diagnostic process of enteric diseases was based on the culture method which demanded skilled staff and was a time-consuming procedure. The development of molecular diagnostics and other diagnostic technologies revolutionized the enteric disease testing market over the last decade. The increasing mortality rate due to these conditions and the cost efficiency of technologically advanced diagnostic systems are expected to drive the demand for early diagnosis of these conditions.

Initial symptoms associated with enteric diseases include abdominal cramps, vomiting, nausea, and anorexia, which can progress to severe conditions characterized by substantial fluid and nutrient loss from the body. The vulnerability of pediatric and geriatric age groups to these diseases is sensitive due to their weakened immune systems. According to the Bill and Melinda Gates Foundation, annually, approximately 500,000 young children under the age of 5 succumb to enteric and diarrheal diseases, predominantly in developing nations. Furthermore, an estimated 25,000 children annually lose their lives to enteric fever, primarily affecting regions lacking access to safe water and adequate sanitation facilities.

The mild initial symptoms of enteric diseases are sometimes overlooked, which poses a significant constraint to the market. These diseases have emerged as a leading cause of morbidity and mortality globally, particularly in developing countries with inadequate drainage and sanitation infrastructure. In terms of incidence and epidemiology, it is estimated that developing nations contribute to more than 85% of the total enteric infection cases.

Browse through Grand View Research's Medical Devices Industry Research Reports.

  • The global molecular diagnostics market size was estimated at USD 15.20 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2030.
  • The global vaccine market size was estimated at USD 76.08 billion in 2023 and is expected to grow at a CAGR of 5.74% from 2024 to 2030.

Enteric Disease Testing Market Segmentation

Grand View Research has segmented the global enteric disease testing market on the basis of disease type, and region:

Enteric Disease Testing Disease Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Bacterial Enteric Disease
  • Viral Enteric Disease
    • Rotavirus
    • Norovirus
  • Parasitic Enteric Disease

Enteric Disease Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Key Companies profiled:

  • Abbott
  • BD
  • Biomerica
  • BIOMÉRIEUX
  • Bio-Rad Laboratories, Inc.
  • Cepheid
  • Coris BioConcept
  • DiaSorin S.p.A.
  • Meridian Bioscience
  • Quest Diagnostics Incorporated

Key Enteric Disease Testing Company Insights

The players are involved in technological advancement and new product development in order to sustain their position in the market and offer cost-efficient solutions. For instance, in May 2022, BD announced the launch of a fully automated, ultra-high-throughput molecular diagnostic platform for infectious diseases in the U.S. Additionally, in February 2021, Thermo Fisher Scientific, Inc. announced the acquisition of Mesa Biotech, which aims to expand the benefits of molecular diagnostics at the point of care.

Furthermore, In January 2019, DiaSorin S.p.A. announced the launch of the FDA-approved Calprotectin test, LIAISON, for quantitative calprotectin assays in stool samples. This comes on the heels of the recent strategic partnership announced by DiaSorin S.p.A. with Meridian Bioscience to sell a stool antigen test. 

Order a free sample PDF of the Enteric Disease Testing Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.